Watson David O. — SEC Form 4 filings
SEC reporting owner CIK 1657719. 27 Form 4 filings on record with FilingPulse; latest filed 2026-05-14.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2024-01-17 to 2026-05-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 21 legs across 21 filings — 102,951 shares, $2,979,524 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: sale of 20,000 shares @ $26.17 ($523,400) in Apellis Pharmaceuticals, Inc., filed 2025-09-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) | General Counsel | 27 | — | 21 legs · 102,951 sh · $2,979,524 | 36 |
Form 4 filings — Watson David O.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Code (U): 144,517 · Code (U): 10,000 · Code (U): 50,136 · Grant/award (A): 41,250 · Disposition to issuer (D): 41,250 · Grant/award (A): 28,508 · +17 more | EDGAR |
| 2026-01-30 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 55,986 @ $0 | EDGAR |
| 2026-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 7,832 @ $21.77 | EDGAR |
| 2026-01-21 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 2,475 @ $19.79 | EDGAR |
| 2026-01-15 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,780 @ $22.19 | EDGAR |
| 2026-01-09 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Option exercise (M): 888 @ $14.95 · Option exercise (M): 888 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,000 @ $24.49 | EDGAR |
| 2025-11-18 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,000 @ $20.06 | EDGAR |
| 2025-10-17 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,000 @ $25.22 | EDGAR |
| 2025-09-18 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,000 @ $24.34 | EDGAR |
| 2025-09-12 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 20,000 @ $26.17 | EDGAR |
| 2025-08-19 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,000 @ $27.80 | EDGAR |
| 2025-07-18 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,000 @ $19.55 | EDGAR |
| 2025-06-18 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,000 @ $18.77 | EDGAR |
| 2025-06-11 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 82,500 (derivative) @ $19.39 | EDGAR |
| 2025-03-06 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Gift (G): 6,667 @ $0 · Gift (G): 6,667 @ $0 · Sale (S): 5,569 @ $25.10 | EDGAR |
| 2025-01-30 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 695 @ $29.52 | EDGAR |
| 2025-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 3,323 @ $30.43 | EDGAR |
| 2025-01-21 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 2,201 @ $29.96 · Grant/award (A): 42,762 @ $0 | EDGAR |
| 2025-01-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 4,965 @ $28.70 | EDGAR |
| 2024-12-13 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 5,000 @ $34.23 | EDGAR |
| 2024-09-30 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Gift (G): 10,569 @ $0 · Gift (G): 10,569 @ $0 | EDGAR |
| 2024-03-08 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Option exercise (M): 3,762 @ $13.85 · Option exercise (M): 3,762 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 781 @ $67.77 | EDGAR |
| 2024-01-31 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 906 @ $64.14 | EDGAR |
| 2024-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 4,184 @ $65.00 | EDGAR |
| 2024-01-17 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 23,748 @ $0 · Sale (S): 4,240 @ $66.81 · Grant/award (A): 34,533 (derivative) @ $66.30 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1657719 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →